Loading...
OTCM
NPHC
Market cap2mUSD
Jul 09, Last price  
0.00USD
1D
0.00%
1Q
50.00%
Jan 2017
-96.34%
IPO
-99.79%
Name

Nutra Pharma Corp

Chart & Performance

D1W1MN
OTCM:NPHC chart
P/E
P/S
5.57
EPS
Div Yield, %
Shrs. gr., 5y
19.54%
Rev. gr., 5y
24.16%
Revenues
385k
-12.09%
0020,20004,045618,0101,432,056159,599203,290122,198594,505291,302168,356120,979130,596104,39351,89797,735438,274385,307
Net income
-2m
L
-7,986,853-5,152,164-2,431,178-164,951-4,162,108-2,301,641-3,061,464-4,397,198-3,612,351-4,342,964-2,532,985-5,391,981-3,447,613-4,028,748-3,884,695-6,591,442-769,184-13,095,5218,176,871-2,047,392
CFO
-1m
L+52.66%
-1,512,314-1,529,477-1,737,081-805,367-976,094-1,956,102-1,358,173-1,888,111-721,242-531,037-148,129-1,018,188-1,356,498-1,138,347-999,949-743,659-878,086-1,744,469-762,432-1,163,964

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Nutra Pharma Corp. (NPHC) operates as a biopharmaceutical firm specializing in obtaining, licensing, and bringing to market a variety of pharmaceutical products, cutting-edge technologies, and both homeopathic and ethical medications. The company primarily targets the U.S. market, focusing its efforts on managing conditions such as pain, neurological ailments, cancer, autoimmune diseases, and infectious diseases. Its current commercial offerings include: Nyloxin and Nyloxin Extra Strength: These products are distributed as an oral spray for alleviating lower back pain, migraines, neck and shoulder discomfort, cramps, and neuropathic pain, and as a topical gel to relieve joint pain, arthritis, and repetitive stress injuries. Pet Pain-Away: An over-the-counter (OTC) homeopathic, non-narcotic, and non-addictive solution for chronic pain in household pets. Luxury Feet: An OTC pain reliever and anti-inflammatory designed to ease foot pain or discomfort specifically caused by high heels and stilettos. Nyloxin Military Strength: A specialized formulation for pain relief aimed at the United States Military and Veteran's Administration. Equine Pain-Away: An OTC topical pain management product for horses. Beyond its existing portfolio, Nutra Pharma Corp. is also advancing several pipeline candidates: RPI-78M: In development to treat neurological conditions such as multiple sclerosis, adrenomyeloneuropathy, and amyotrophic lateral sclerosis, alongside autoimmune diseases like rheumatoid arthritis and myasthenia gravis. RPI-MN: Under investigation for viral diseases, including human immunodeficiency virus (HIV/AIDS) and herpes, as well as for general antiviral applications. RPI-78: Being developed for applications in pain and arthritis. RPI-70: Also in development for pain relief. Founded in 2000, the company is headquartered in Plantation, Florida.
IPO date
Oct 09, 2001
Employees
4
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT